Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | NAMPT | P43490 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3572556 | 0.90 | L3MBTL1 (0.50) | L3MBTL1SMN1; SMN2NPC1LMNATSHR | |
| SCHEMBL3576758 | 0.89 | KDR (0.52) | L3MBTL1SMN1; SMN2NPC1RAB9ANAMPT | |
| SCHEMBL3578306 | 0.85 | ROCK2 (0.52) | SMN1; SMN2NPC1LMNARAB9AMEN1 | |
| SCHEMBL3575031 | 0.83 | ROCK2 (0.55) | SMN1; SMN2NPC1LMNARAB9AMEN1 | |
| SCHEMBL3582443 | 0.81 | KDR (0.46) | SMN1; SMN2NPC1LMNARAB9AMEN1 | |
| SCHEMBL3581857 | 0.80 | SMN1; SMN2 (0.42) | SMN1; SMN2NPC1TSHRRAB9AKMT2A | |
| SCHEMBL4719226 | 0.80 | KDR (0.58) | SMN1; SMN2NPC1LMNATSHRRAB9A | |
| SCHEMBL3585366 | 0.79 | L3MBTL1 (0.53) | L3MBTL1SMN1; SMN2NPC1LMNATSHR | |
| SCHEMBL3581177 | 0.78 | ROCK2 (0.41) | SMN1; SMN2NPC1LMNARAB9AMEN1 | |
| SCHEMBL3582789 | 0.78 | AURKB (0.42) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | US | disclosed |
| EP-1863805-A1 | PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006082373-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | TEK, TYMP, TIE1 | L3MBTL1 3183/4885SMN1; SMN2 3824/4885NPC1 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.